At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 177 enrolled
Drug / intervention
Fampridine-SR b.i.d. (Twice Daily)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating Fampridine-SR b.i.d. (Twice Daily) for Multiple Sclerosis. Completed, enrolled 177 participants across 22 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan Corporation sponsored protocol. Subjects are eligible regardless of whether they received active drug or placebo during their participation in the previous study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
First PostedApr 2008
Primary CompletionJan 2011
Study CompletionApr 2011
TodayJul 2026
First PostedApr 9, 2008
Enrollment StartNov 1, 2003
Primary CompletionJan 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 18.2 years ago
Interventions
Fampridine-SR b.i.d. (Twice Daily)drug
Dosage form - tablets.